Early 1,25-dihydroxyvitamin D 3 (VD 3 ) therapy during the course of renal failure prevents the downregulation of VD 3 receptor (VDR), calcium-sensing receptor (CaSR) or p21, and the parathyroid (PT) growth. We hypothesized that VD 3 could restore the decreased expressions of VDR and CaSR, and cause regression in enlarged PT glands. 5/6 nephrectomized rats fed high-phosphorus diet were killed at 1, 3, 5, or 7 days and at 2, 3, 4, 8, or 12 weeks. VD 3 -treated rats were given VD 3 intraperitoneally for 1, 2, 3, or 4 weeks, starting 8 weeks after 5/6 nephrectomy. PT glands were weighed and subjected to immunohistochemical analyses for VDR, CaSR, p21, Ki67, and Tdt-mediated dUTP nick end-labeling (TUNEL) assay. The area per cell was measured as the parameter of cell size. The expression of VDR and p21 began to decrease at day 1, and Ki67 increased at day 3, but decreased thereafter. There was a significant increase in PT gland weight to week 12 with the increase of cell size. VD 3 treatment significantly increased both VDR and CaSR expressions 2 weeks after the start of injection, and reduced the PT gland weight at week 3 with significant increase of TUNEL-positive cells and decrease of cell size. Our results suggest that PT growth in uremic rats involves both PT cell proliferation and hypertrophy, in association with the reduction of VDR, CaSR, and p21 expressions. In addition, VD 3 treatment could reverse PT hyperplasia and hypertrophy via restoration of these proteins.
Secondary hyperparathyroidism is an inevitable complication of chronic renal failure. It is characterized by an increase in the synthesis and secretion of parathyroid hormone (PTH), mainly due to disturbances of calcium (Ca), phosphate (Pi), and 1,25-dihydroxyvitamin D 3 (VD 3 ) metabolism. It is also known that a continuous increase in PTH production is associated with parathyroid (PT) hyperplasia. The expression of VD 3 receptor (VDR) correlates negatively with the proliferative activity of PT glands in patients with secondary hyperparathyroidism. 1 Liu et al. 2 defined a functional VD 3responsive element within the p21 promoter mediating this induction. In human PT glands, we demonstrated that the reduced expression of p21, in a VDR-dependent manner, is a pathogenic factor for nodular PT glands in uremic patients with secondary hyperparathyroidism, by using immunohistochemical analyses. 3 Ca-sensing receptor (CaSR) may also play a role in the regulation of PT hyperplasia. 4 Naveh-Many et al. 5 revealed that Ca deprivation, together with VD 3 deficiency, resulted in marked enhancement of the proliferative activity of PT glands in uremic rats, using the proliferating cell nuclear antigen. In this regard, Ho et al. 6 reported that CaSR knockout mice had enlarged PT glands. Moreover, Wada et al. 7 indicated that administration of the calcimimetic compound NPS R-568, a CaSR agonist, led to the suppression of PT cell proliferation in experimental uremic rats. These reports suggest that the downregulation of either VDR or CaSR could play a crucial role in the pathogenesis of PT growth in secondary hyperparathyroidism. The first aim of the present study was to assess the pathogenesis of PT growth, by examining the time course of VDR, CaSR, and p21 expressions immunohistochemically.
Low expressions of VDR, CaSR, and p21 were observed in the PT glands of experimental uremic rats with secondary hyperparathyroidism. 4, 5, 8 Denda et al. 9 reported that early administration of VD 3 prevented the reduction of VDR. Cozzolino et al. 10 showed that VD 3 treatment induced p21 expression in hyperplastic PT glands in a model of early uremia. VD 3 has been known to prevent cell proliferation and enhance cell maturation. These effects were initially described in lymphoid cells 2 and more recently in keratinocytes and myocytes. [11] [12] [13] The importance of VD 3 in the PT hyperplasia of experimental uremic rats was first described by Szabo et al. 14 They were able to inhibit PT cell proliferation completely when VD 3 was administered at the start of uremia, but not when given later (21 days after 5/6 nephrectomy). However, Reichel et al. 15 could observe a reduction of PT gland weight by intermittent administration of VD 3 on the 21st day of uremia. Fukagawa et al. 16 demonstrated that pharmacological doses of VD 3 repressed c-myc expression in the PT glands of uremic rats and suggested that VD 3 might suppress PT hyperplasia through this pathway. They also reported the regression of PT hyperplasia in hemodialysis patients by VD 3 pulse therapy. 17 In contrast, Quarles et al. 18 reported the failure of VD 3 treatment to reduce PT hyperplasia in hemodialysis patients. It remains controversial whether VD 3 could induce regression of enlarged PT glands. Thus, in the present study, we hypothesized that VD 3 could restore the decreased VDR, CaSR, and p21 expressions with a resultant regression of PT hyperplasia.
RESULTS

Protocol 1
Biochemical determinations and PT gland weight. Table 1 shows serum concentrations of creatinine (Cr), Ca, Pi, PTH and VD 3 in normal control rats (NR) and uremic rats for all experimental conditions tested (UR-1w, 2w, 3w, 4w). After 5/6 nephrectomy, the serum concentration of Cr increased from week 1-3 and then decreased. In almost all uremic rats, a compensatory renal hypertrophy was observed at post mortem, which was considered to be the cause of the improved renal function (figure not shown). Serum Ca concentrations significantly decreased after partial nephrectomy, probably due to the elevated Pi levels. Changes in PTH levels were similar to those of Cr. PTH was significantly high from 2 weeks after 5/6 nephrectomy (Po0.01), but decreased in week 4. The serum level of VD 3 was significantly decreased in almost all uremic rats compared to NR.
Expressions of VDR, CaSR and p21 proteins. We examined immunohistochemical staining for VDR, CaSR, and p21 protein in PT glands resected from rats of the corresponding experimental groups. Immunohistochemical staining for VDR and p21 protein revealed mainly nuclear localization. CaSR protein was detected in the cell membrane and cytoplasm. Representative pictures are shown in Figure 1 . The labeling index (LI) of each group is depicted in Table 2 . For the normal group, many cells showed positive nuclear staining for VDR protein (Figure 1a ). VDR-positive cells decreased time dependently. In the UR-4w group, few VDRpositive cells were noted ( Figure 1d ). VDR-LI diminished significantly 1 week after partial nephrectomy compared with NR (Po0.01, Table 2 ). The expression of CaSR protein was enhanced in the PT glands of NR ( Figure 1b ). CaSR-LI also decreased in a time-dependent manner from week 1 like VDR-LI. In NR, many cells showed positive staining with p21 protein (Figure 1c ) and the number of positively stained cells decreased gradually. The p21-LI also decreased significantly from week 1. VDR-LI, CaSR-LI, and p21-LI significantly negatively correlated with PT gland weight (Po0.01, r ¼ À0.40, À0.62, and À0.65, respectively), but not with Ki67-LI.
PT hyperplasia and hypertrophy. PT glands were weighed after removal of all thyroid tissue surrounding the glands. The PT gland weight increased in a time-dependent manner after the onset of renal failure ( Table 2 ). The gland weight of uremic rats increased significantly from week 3 (Po0.01).
Immunohistochemical staining for Ki67 antigen revealed mainly nuclear localization (figure not shown). The expression of Ki67 antigen was immediately enhanced after 5/6 nephrectomy (within 1 week) but diminished thereafter ( Table 2 ). The cell size (CS) index, which is the parameter of CS, increased significantly from 3 weeks after 5/6 nephrectomy. PT gland weight did not correlate with Ki67-LI, but correlated significantly with the CS index (Po0.01, r ¼ 0.55).
There was significant correlation between the CS index and either CaSR-LI (Po0.01, r ¼ À0.63) or serum Pi levels (Po0.01, r ¼ 0.44).
Protocol 2
Expressions of VDR, CaSR, p21 proteins, and Ki67 antigen. To assess if the changes in VDR, CaSR, and p21 proteins precede the onset of PT cell proliferation, we examined the time course of these proteins and Ki67 antigen within 7 days. Table 3 shows the labeling indices of each protein and PT gland weight in the experimental rats. Ki67-LI, as well as PT gland weight, significantly increased in day 3 (Po0.01, Figure 2 ). Both VDR-LI and p21-LI reduced from day 1 significantly (Po0.05, each; Figure 1g , i). On the other hand, CaSR-LI decreased from day 5 (Figure 1h ), which was later than the start of cell proliferation. Within first 7 days after the onset of renal failure, there was no change in the CS index.
Protocol 3
Previous reports did not confirm that VD 3 treatment could induce regression of hyperplastic PT glands or restoration of VDR, CaSR, and p21 expression. [14] [15] [16] [18] [19] [20] [21] In the present study, 5/6 nephrectomized rats fed high-phosphorus diet for 8 weeks were treated with VD 3 for 1, 2, 3, or 4 weeks (UVD-9w, -10w, -11w, or -12w).
Biochemical determinations. Table 4 shows serum concentrations of Cr, Ca, Pi, PTH, and VD 3 in sham-operated control rats (Sx-12w), uremic control rats (UR-8w and -12w) and VD 3 -treated rats (UVD-9w, -10w, -11w, and -12w). In all UVD rats, serum Cr concentrations did not differ as compared to UR-8w and UR-12w. After the VD 3 administration, Ca concentration increased and Pi level decreased (but not significantly). PTH level in UVD-12w was significantly lower than in UR-8w and UR-12w (Po0.05, each). Serum VD 3 concentrations increased significantly 2 weeks after start of the administration. We also measured the serum VD 3 concentration at 1, 2, 3, 6, 12, 24, and 48 h after the injection in UR-8w (15-week-old, n ¼ 8). The serum VD 3 concentration reached its peak level at 12 h and its concentration returned to the baseline level within 48 h (data not shown).
Expressions of VDR, CaSR, p21 proteins and Ki67 antigen. Figure 3 depicts the immunohistochemical staining of VDR, CaSR, and p21 protein in Sx-12w, UR-12w, and UVD-12w rats. VD 3 treatment enhanced the expression levels of all proteins. The LIs of these proteins are shown in Table 5 . Both VDR-LI and CaSR-LI were significantly enhanced at 2 weeks after the start of treatment (Po0.01, each) and p21-LI was at 4 weeks (Po0.05), compared with UR-8w. These LIs were significantly higher in UVD-12w than those in UR-12w (Po0.01, each). Four weeks after the start of VD 3 treatment (UVD-12w), Ki67-LI significantly decreased (Po0.01).
PT regression. VD 3 treatment resulted in a significant reduction of PT gland weight at week 3 (Table 5 ). To elucidate whether the VD 3 -induced reduction in the volume of hyperplastic PT glands is associated with cell death or reduction of hypertrophy, we counted the number of Tdtmediated dUTP nick end-labeling (TUNEL)-positive cells and measured the average area per cell, expressing as CS index, in randomly selected areas on each specimen (Figure 3 ). TUNEL-LI in UVD-12w was significantly higher than in UR-8w and -12w (Po0.01, each; Table 5 ). In the UVD group, the CS index decreased gradually after the start of VD 3 administration ( Table 5 and Figure 3 ). These results indicate that VD 3 treatment can lead not only to cell death, but also to reduction of cell hypertrophy.
DISCUSSION
The first major finding of the present study was that reduced expressions of VDR and p21 preceded the start of PT cell proliferation, during the course of renal failure in the 5/6 nephrectomized rats (Table 3 ). While the reduction of VDR and CaSR in enlarged PT glands of uremic patients and models has already been described, 1, 3, 4, [22] [23] [24] [25] it is not clear whether the reduced expression levels of VDR or CaSR lead to PT cell proliferation. We previously reported that the VDR-dependent reduction of p21 expression contributes to the pathogenesis of PT hyperplasia in hemodialysis patients with secondary hyperparathyroidism. 3 In the present study of uremic rat model, significant decreases of both VDR and p21 expressions occurred 1 day after 5/6 nephrectomy, while the PT hyperplasia started at day 3. These results suggest that the downregulation of both VDR and p21 may play a crucial role in the pathogenesis of PT hyperplasia during the course of secondary hyperparathyroidism. This conclusion was confirmed by the finding that the expression of VDR and p21 correlated negatively with PT gland weight (Po0.01, each; figure not shown). On the other hand, the decrease of CaSR (day 5) was later than the increase of a disease attributed to loss-of-function mutations in the CaSR gene, 27 and in the CaSR knockout mice. 6 Wada et al. 7 demonstrated that a calcimimetic compound NPS R-568 inhibited PT cell proliferation in partial nephrectomized rat model. Under these circumstances, it is possible that PT cell proliferation triggers a cascade of events that lead to downregulation of CaSR and then this CaSR reduction accelerates PT growth. The second major finding was that the PT growth in experimental rat model not only involves PT cell proliferation but also PT cell hypertrophy. In the present study, Ki67 increased within 1 week after 5/6 nephrectomy (Table 3 ) and then decreased in a time-dependent manner ( Table 2 ). In spite of the reduction in Ki67, PT growth continued. The gradual increase in the CS index ( Table 2 ) might be the cause of persistent PT enlargement. Many previous reports have shown that the hyperplasia begins within 1 week following partial nephrectomy and high-phosphorus diet. 8, 10, 28, 26 However, there was no report indicating the relationship between PT enlargement and cell hypertrophy. Nagano et al. 29 reported that the regression of cell hypertrophy was the mechanism of regression of PTH growth by sevelamer hydrochloride administration. This report suggests that the serum Pi concentration might be related to the mechanism of PT cell hypertrophy. In our protocol 1, the significant correlation between the CS index and serum Pi levels was concordant with Nagano et al.'s report.
The third finding of the present study was that VD 3 administration reduced the volume of the enlarged PT glands and restored the diminished VDR, CaSR, and p21 expression levels. In our data, TUNEL-positive cells increased and the CS index decreased significantly by VD 3 treatment (Table 5 ). These results suggest that VD 3 treatment could induce both PT cell death and reduction of cell hypertrophy. Previous reports demonstrated that administration of active VD 3 early in the course of renal failure prevented PT hyperplasia. 9, 10, 15 Our results showed for the first time that VD 3 administration caused regression of enlarged PT glands during the course of renal failure. There is controversy regarding the effect of VD 3 treatment on PT gland size in some clinical studies. Using ultrasonography, Fukagawa et al. 17 reported a significant regression of PT hyperplasia in hemodialysis patients following 12-week VD 3 pulse therapy. In contrast, Quarles et al. 18 reported failure of 36-week intermittent intravenous or oral VD 3 treatment to reduce PT hyperplasia in hemodialysis patients, as examined by ultrasonography and/or magnetic resonance imaging. The difference between these two reports suggests that small PT glands such as diffuse hyperplasia are more likely to undergo reduction in their size than larger glands. Using percutaneous maxacalcitol injection therapy technique, Shiizaki et al. 19 also demonstrated PT regression by induction of apoptosis in hemodialysis patients with secondary hyperparathyroidism. Our results were concordant with Shiizaki et al.'s report and, furthermore, indicated that the improvement of hypertrophy might also play an important role in PT regression. The reduction of both cell number and cell volume may be involved in PT regression.
Previous studies reported that early VD 3 therapy during the course of renal failure inhibits the downregulation of VDR, CaSR and p21. 9, 10, 15 We indicated that VD 3 could restore the expression levels of VDR, CaSR, and p21 in enlarged PT glands. With regard to CaSR, the presence of VD 3 response element in the upstream of CaSR gene was confirmed by Canaff and Hendy. 30 Liu et al. 2 reported that p21 WAF1,CIP1 gene was transcriptionally activated by VD 3 in a VDR-dependent, but p53-independent, manner and defined a functional VD 3 response element within the p21 promoter mediating this induction. In the present study, the upregulation of both VDR and CaSR preceded the reduction of PT gland weight, Ki67, and the CS index, and the increase of TUNEL-positive cells ( Table 4 ). In this regard, restoration of both VDR and CaSR may contribute not only to arrest PT hyperplasia but also to PT cell death or reduction of cell hypertrophy through certain pathways.
In conclusion, our results suggest that PT growth in uremic rats involves both PT cell hyperplasia and hypertrophy, in association with the reduction of VDR, CaSR, and p21 expressions. In addition, VD 3 treatment may induce reversal of PT hyperplasia and hypertrophy via restoration of these proteins.
MATERIALS AND METHODS Study design
The study was conducted in male Sprague-Dawley rats (age 6 weeks, body weight 4200 g). All rats were killed under ether anesthesia. For 5/6 nephrectomy, 2/3 of the left kidney was cut and the right kidney was excised. In protocol 1, the rats were divided at random into the following experimental groups: NR, 6-week-old, as control (n ¼ 9); uremic rats fed high-phosphorus diet (Ca 1.0%, Pi 0.8%, VD 3 240 IU/100 g; Kyudo Co. Ltd, Saga, Japan) for 1, 2, 3, and 4 weeks (UR-1w (n ¼ 7), UR-2w (n ¼ 7), UR-3w (n ¼ 7) and UR-4w (n ¼ 7), respectively). The high-phosphorus diet was selected based on the previous study of Slatopolsky et al. 31 To examine if the changes in VDR, CaSR, and p21 precede the onset of PT cell proliferation, in protocol 2, the rats were divided as follows: NR, 6-week-old, as control (n ¼ 9); uremic rats that were killed 1, 3, 5, and 7 days after 5/6 nephrectomy (UR-1d (n ¼ 7), UR-3d (n ¼ 7), UR-5d (n ¼ 7) and UR-7d (n ¼ 7), respectively).
In protocol 3, the rats were divided into the following groups: sham-operated rats as control (Sx-12w (19-week-old, n ¼ 7)); uremic control rats fed high-phosphorus diet for 8 and 12 weeks (UR-8w (15-week-old, n ¼ 7) and UR-12w (19-week-old, n ¼ 10), respectively). VD 3 -treated rats were fed the high-phosphorus diet mentioned above for 12 weeks, and then treated with VD 3 (8 ng/kg body weight, twice per week) for 1, 2, 3, and 4 weeks from 9th week (UVD-9w (n ¼ 5), UVD-10w (n ¼ 5), UVD-11w (n ¼ 5) and UVD-12w (19-week-old, n ¼ 6: the same age as Sx-12w and UR-12w), respectively). VD 3 was administered intraperitoneally in 0.5 ml phosphate-buffered saline. The dose of VD 3 was based on the study of Finch et al. 32 Blood was withdrawn immediately and placed in ice and the plasma was kept at À801C for later analysis. PT glands were surgically removed and weighed on a GR-202 microbalance (AND Co., Tokyo, Japan). The harvested PT glands were kept in 10% formaldehyde overnight and then transferred into 70% ethanol in water. This experiment was reviewed by the Ethics Committee of Animal Experimentation, Faculty of Medicine, Kyushu University and carried out under the Guidelines for Animal Experiments of the Faculty of Medicine, Kyushu University and the law (no. 105) and notification (no. 6) of the government.
Biochemical determinations
Serum Cr, Ca, and Pi were measured using an autoanalyzer (Hitachi Instruments, Tokyo, Japan). Intact PTH levels were determined by an immunoradiometric assay specific for intact rat PTH (Immunotopics Inc., San Clemente, CA, USA). The level of VD 3 was measured by the 1,25(OH) 2 D RIA kit (Immunodiagnostic Systems, Boldon, UK).
Immunohistochemistry
All specimens were fixed in 10% formalin and were routinely processed to paraffin. Formalin-fixed, paraffin-embedded tissue sections were serially cut at 3 mm and mounted on aminopropyltriethoxysilane-coated glass slides. These sections were deparaffinized in xylene and dehydrated through an ethanol series. We carried out the immunohistochemical staining using previously described methods. 3 The sections were treated with 10 mM citrate, pH 6.0, in a microwave oven for antigen retrieval before immunohistochemical staining. The serial sections were then incubated with the primary antibodies at 41C overnight. The antibodies used included anti-VDR antibody (Santa Cruz Biotechnology Inc., CA, USA), anti-CaSR antibody (Affinity Bioreagents Inc., CO, USA), anti-p21 antibody (Santa Cruz Biotechnology) and anti-Ki67 antibody (Novocastra Laboratories Ltd, Newcastle, UK). Immunostaining was performed with the Elite avidin biotin peroxidase kit (Nichirei, Tokyo, Japan) according to the specifications provided by the manufacturer. For counting, all of immunohistochemical analyses were performed with serial sections.
Tdt-mediated dUTP nick end-labeling assay
Fragmented DNA was detected in cell nuclei using a modification of previously described methods. 33 Each paraffin section of PT tissues was deparaffinized, dehydrated, blocked with 0.3% H 2 O 2 in methanol for 30 min at room temperature and then treated with 50 ml of TUNEL reaction mixture (10 Â Tdt 5 ml, 1 Â nucleotide mixture 45 ml, in situ detection kit, peroxidase; Roche, Mannheim, Germany) and incubated in a humidity chamber at 371C for 1 h. Subsequently, 50 ml converter POD (anti-fluorescein antibody, Fab fragment from sheep, conjugated with horseradish peroxidase) was applied to each specimen, and the slides were incubated for 30 min at 371C in a humidified chamber. After the reaction with converter POD, the sites of horseradish peroxidase were visualized with 3, 3-diaminobenzidine and H 2 O 2 . Slides were counterstained with methyl green for 2 min.
Quantitation
The quantitative method was described previously. 3 Only distinct immunostaining for CaSR, VDR, p21, Ki67, and TUNEL was considered positive immunoreactivity. The distribution of immunoreactivity was analyzed by quantifying positive staining in randomly selected areas on each specimen without prior knowledge of either diagnosis or outcome. The number of cells expressing VDR, p21, Ki67, and TUNEL were determined by counting a minimum of 1000 cells per slide using NIH image analysis freeware. The brightness and contrast of each image were uniformly enhanced or diminished by Adobe Photoshop version 5.0 followed by analysis using NIH image freeware version 1.62. With regard to VDR, p21, Ki67, and TUNEL staining, in order to avoid the influence of nonspecific positive staining, plots of less than 30 pixels were excluded. The percentage of positive immunoreactive area per total area (CaSR) and the number of positive immunoreactive nuclei per 1000 parenchymal cells (VDR, p21, Ki67, TUNEL) were expressed as the LI. CaSR, VDR, p21, Ki67, and TUNEL immunoreactive cells were randomly counted over a minimum of five fields in more than three sections. Repeat recounts for CaSR, VDR, Ki67, and TUNEL in 10% of the PT glands conducted in a blind fashion showed variability of LIs of p75% from the original counts.
Measurement of cell size
To elucidate cell hypertrophy, the average area per cell was expressed as the CS index by using the hematoxylin staining section: CS index ðmm 2 =cellÞ ¼ T ðmm 2 Þ=N; where T is the total area per visual field and N the total number of PT cells per visual field.
Statistical analysis
Data are expressed as mean7s.e.m. All statistics were analyzed by using the StatView program (Abacus Concepts, Berkeley, CA, USA). One-way analysis of variance followed by Student's t-test with Bonferroni correction was used when indicated for comparison of each experimental group. A linear regression analysis was also used for the relationship between each parameter. A P-value less than 0.05 was considered statistically significant.
